Number of combined performance obligation at contract inception.

No definition available.

Name:	cara_NumberOfCombinedPerformanceObligationAtContractInception
Namespace Prefix:	cara_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of performance obligations for revenue recognized.

+ References

No definition available.

+ Details

Name:	cara_NumberOfPerformanceObligationsForRevenueRecognized
Namespace Prefix:	cara_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Premium from sale of stock.

+ References

No definition available.

+ Details

Name:	cara_PremiumFromSaleOfStock
Namespace Prefix:	cara_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The premium related to the common stock investment upon regulatory approval of CR845.

+ References

No definition available.

+ Details

Name:	cara_PremiumOnCommonStockInvestmentPercentage
Namespace Prefix:	cara_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of proceeds from milestone payments.

+ References

No definition available.

+ Details

Name:	cara_ProceedsFromMilestonePayments
Namespace Prefix:	cara_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The length of time used to set the price in the common stock investment upon regulatory approval of CR845.

+ References

No definition available.

+ Details

Name:	cara_StockIssuancePriceMeasurementPeriod
Namespace Prefix:	cara_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Payments on obligations.

+ References

No definition available.

+ Details

Name:	cara_UpfrontPaymentsOnObligations
Namespace Prefix:	cara_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(b))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_AccountsReceivableRelatedPartiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044

+ Details

Name:	us-gaap_ContractWithCustomerAssetNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=cara_CommercialSupplyRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cara_LicenseAndMilestoneFeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cara_CollaborativeRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cara_ClinicalCompoundRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_ViforFreseniusMedicalCareRenalPharmaLtdAgreementNo2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cara_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_ViforFreseniusMedicalCareRenalPharmaLtdAgreementNo1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_CslViforMaruishiAndCkdpAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_CslViforAndCkdpAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_LicenseAgreementWithMaruishiPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_LicenseAgreementWithChongKunDangPharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cara_MaruishiPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cara_ViforInternationalLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cara_CslViforMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cara_CommercialSupplyRevenueWithNoAssociatedCostsOfGoodsSoldMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cara_CommercialSupplyRevenueWithAssociatedCostsOfGoodsSoldMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue Recognition - Additional Information (Detail) $ / shares in Units, $ in Thousands		1 Months Ended			11 Months Ended	12 Months Ended
	May 17, 2018 item	Apr. 30, 2022 USD ($) item	Jan. 31, 2022 USD ($)	Oct. 31, 2021 USD ($) item $ / shares shares	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) item	Dec. 31, 2021 USD ($) item	Dec. 31, 2020 USD ($)	Dec. 31, 2018 USD ($) item
Collaboration Arrangement [Line Items]
Accounts receivable, net - related party					$ 3,260	$ 3,260
Total revenue						41,867	$ 23,028	$ 135,082
Research and development expense						91,879	82,701	107,851
Commercial Supply Revenue
Collaboration Arrangement [Line Items]
Total revenue						10,223	701
License and Milestone Fees
Collaboration Arrangement [Line Items]
Total revenue						15,000	21,223	134,439
Royalty Revenue
Collaboration Arrangement [Line Items]
Total revenue						72
Collaborative Revenue
Collaboration Arrangement [Line Items]
Total revenue						16,572	706
Clinical Compound Revenue
Collaboration Arrangement [Line Items]
Total revenue							398	643
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member]
Collaboration Arrangement [Line Items]
Number of performance obligations for revenue recognized \| item									2
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] \| License and Milestone Fees
Collaboration Arrangement [Line Items]
Total revenue								22,262
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] \| License and Milestone Fees \| Regulatory Milestones [Member]
Collaboration Arrangement [Line Items]
Number Of Combined Performance Obligation At Contract Inception \| item		1
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member] \| License and Milestone Fees
Collaboration Arrangement [Line Items]
Number of performance obligations for revenue recognized \| item	1
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member] \| License and Milestone Fees \| Regulatory Milestones [Member]
Collaboration Arrangement [Line Items]
Proceeds from milestone payments							$ 15,000
Number of performance obligations for revenue recognized \| item							1
CSL Vifor, Maruishi and CKDP Agreements [Member]
Collaboration Arrangement [Line Items]
Accounts receivable, net - related party							$ 0
Other contract Assets					0	$ 0	0
CSL Vifor and CKDP Agreements [Member] \| License and Milestone Fees
Collaboration Arrangement [Line Items]
Number of performance obligations for revenue recognized \| item						1
Maruishi Agreement [Member]
Collaboration Arrangement [Line Items]
Remaining performance obligations					0	$ 0
Maruishi Agreement [Member] \| License and Milestone Fees
Collaboration Arrangement [Line Items]
Total revenue						0	1,192	0
Maruishi Agreement [Member] \| Collaborative Revenue
Collaboration Arrangement [Line Items]
Total revenue						0	706	0
CKDP Agreement [Member] \| License and Milestone Fees
Collaboration Arrangement [Line Items]
Total revenue						0	0	626
Remaining performance obligations					0	0
Maruishi Pharmaceutical Co., Ltd. [Member] \| License and Milestone Fees
Collaboration Arrangement [Line Items]
Total revenue							1,192
Maruishi Pharmaceutical Co., Ltd. [Member] \| Clinical Compound Revenue
Collaboration Arrangement [Line Items]
Total revenue							37	528
Research and development expense							33	476
Vifor International Ltd. [Member] \| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member]
Collaboration Arrangement [Line Items]
Premium from sale of stock									$ 5,444
Upfront payments on obligations									$ 50,000
Remaining performance obligations					0	0
Vifor International Ltd. [Member] \| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member]
Collaboration Arrangement [Line Items]
Proceeds from the sale of common stock				$ 50,000
Common stock, shares issued \| shares				3,282,391
Price per share \| $ / shares				$ 15.23
Percentage of premium on common stock investment				20.00%
Stock Issuance Price Measurement Period				30 days
Number of performance obligations for revenue recognized \| item				1
Premium from sale of stock							5,031
Vifor International Ltd. [Member] \| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member] \| License and Milestone Fees
Collaboration Arrangement [Line Items]
Total revenue								111,551
Premium from sale of stock								11,551
Upfront payments on obligations								100,000
Remaining performance obligations					0	0
CSL Vifor [Member]
Collaboration Arrangement [Line Items]
Accounts receivable, net - related party					3,260	3,260
CSL Vifor [Member] \| Commercial Supply Revenue
Collaboration Arrangement [Line Items]
Total revenue						10,223	701
CSL Vifor [Member] \| Commercial Supply Revenue With No Associated Costs Of Goods Sold [Member]
Collaboration Arrangement [Line Items]
Total revenue			$ 2,295				701
CSL Vifor [Member] \| Commercial Supply Revenue With Associated Costs Of Goods Sold [Member]
Collaboration Arrangement [Line Items]
Total revenue					7,928
Cost of goods sold					$ 7,266
CSL Vifor [Member] \| License and Milestone Fees
Collaboration Arrangement [Line Items]
Total revenue						15,000	20,031	133,813
CSL Vifor [Member] \| Royalty Revenue
Collaboration Arrangement [Line Items]
Total revenue						72
CSL Vifor [Member] \| Collaborative Revenue
Collaboration Arrangement [Line Items]
Total revenue						16,572	0	0
CSL Vifor [Member] \| Clinical Compound Revenue
Collaboration Arrangement [Line Items]
Total revenue							361	115
CSL Vifor [Member] \| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] \| License and Milestone Fees \| Regulatory Milestones [Member]
Collaboration Arrangement [Line Items]
Proceeds from milestone payments		$ 15,000
CSL Vifor [Member] \| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] \| Clinical Compound Revenue
Collaboration Arrangement [Line Items]
Total revenue						$ 0	361	115
Research and development expense							$ 343	$ 108